New Targets for PET Imaging of Myeloma

Recent advances in the treatment of multiple myeloma (MM) have increased the need for accurate diagnosis and detection of minimal residual disease (MRD), disease characterization and localization, and response evaluation and prognostication. Positron emission tomography (PET)/computed tomography (CT...

Full description

Saved in:
Bibliographic Details
Published in:Hemato 2021-12, Vol.2 (4), p.727-738
Main Authors: Revheim, Mona-Elisabeth, Stokke, Caroline, Nørgaard, Jakob Nordberg, Phillips, Hilde Feiring, Sherwani, Alexander Gul, Schjesvold, Fredrik, Connelly, James P.
Format: Article
Language:English
Subjects:
[11C]methionine
[18F]FDG
[18F]fluciclovine
[68Ga]Ga-pentixafor
Amino acids
Anemia
Biopsy
Bone marrow
Brain cancer
Disease
Medical prognosis
Multiple myeloma
Patients
PET/CT
Plasma
Prostate cancer
Radiation therapy
Remission (Medicine)
Tomography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c333t-de5e1d818cd417401e865840de366fca2c0bf8dbba5e45348d8335bf91afa9323
cites cdi_FETCH-LOGICAL-c333t-de5e1d818cd417401e865840de366fca2c0bf8dbba5e45348d8335bf91afa9323
container_end_page 738
container_issue 4
container_start_page 727
container_title Hemato
container_volume 2
creator Revheim, Mona-Elisabeth
Stokke, Caroline
Nørgaard, Jakob Nordberg
Phillips, Hilde Feiring
Sherwani, Alexander Gul
Schjesvold, Fredrik
Connelly, James P.
description Recent advances in the treatment of multiple myeloma (MM) have increased the need for accurate diagnosis and detection of minimal residual disease (MRD), disease characterization and localization, and response evaluation and prognostication. Positron emission tomography (PET)/computed tomography (CT) imaging combines molecular and morphological information and has been shown to be especially valuable in this disease. The most frequently used PET tracer in MM is the glucose analog 18F-fluorodeoxyglucose ([18F]FDG). [18F]FDG PET/CT has a sensitivity for detection of MM between 80% to 100% and is currently the main imaging modality for assessing treatment response and for determining MRD. However, 18F-FDG PET/CT has some limitations, and imaging with alternative tracers that may overcome these constraints should be further explored. This article discusses new targets for PET/CT imaging in the assessment of MM.
doi_str_mv 10.3390/hemato2040049
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_3edbdea5ef9e43cba43c009d920183a4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_3edbdea5ef9e43cba43c009d920183a4</doaj_id><sourcerecordid>2656384123</sourcerecordid><originalsourceid>FETCH-LOGICAL-c333t-de5e1d818cd417401e865840de366fca2c0bf8dbba5e45348d8335bf91afa9323</originalsourceid><addsrcrecordid>eNpVkM1Lw0AQxRdRsNQevQcEb9HZnU2yOUqptlA_DvW8bHZnY0rTrZsU6X9vtCJ6mS8evzc8xi453CCWcPtGremDAAkgyxM2EnmBaY5ZcfpnPmeTrlsDgFAcCslH7PqJPpKViTX1XeJDTF5mq2TRmrrZ1knwyeOBNqE1F-zMm01Hk58-Zq_3s9V0ni6fHxbTu2VqEbFPHWXEneLKOskLCZxUnikJjjDPvTXCQuWVqyqTkcxQKqcQs8qX3HhTosAxWxy5Lpi13sWmNfGgg2n09yHEWpvYN3ZDGslVjgaQL0mircxQAEpXCuAKh23Mro6sXQzve-p6vQ77uB3e1yLPclSSCxxU6VFlY-i6SP7XlYP-Slb_SxY_ATU4aiI</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2656384123</pqid></control><display><type>article</type><title>New Targets for PET Imaging of Myeloma</title><source>Publicly Available Content Database</source><creator>Revheim, Mona-Elisabeth ; Stokke, Caroline ; Nørgaard, Jakob Nordberg ; Phillips, Hilde Feiring ; Sherwani, Alexander Gul ; Schjesvold, Fredrik ; Connelly, James P.</creator><creatorcontrib>Revheim, Mona-Elisabeth ; Stokke, Caroline ; Nørgaard, Jakob Nordberg ; Phillips, Hilde Feiring ; Sherwani, Alexander Gul ; Schjesvold, Fredrik ; Connelly, James P.</creatorcontrib><description>Recent advances in the treatment of multiple myeloma (MM) have increased the need for accurate diagnosis and detection of minimal residual disease (MRD), disease characterization and localization, and response evaluation and prognostication. Positron emission tomography (PET)/computed tomography (CT) imaging combines molecular and morphological information and has been shown to be especially valuable in this disease. The most frequently used PET tracer in MM is the glucose analog 18F-fluorodeoxyglucose ([18F]FDG). [18F]FDG PET/CT has a sensitivity for detection of MM between 80% to 100% and is currently the main imaging modality for assessing treatment response and for determining MRD. However, 18F-FDG PET/CT has some limitations, and imaging with alternative tracers that may overcome these constraints should be further explored. This article discusses new targets for PET/CT imaging in the assessment of MM.</description><identifier>ISSN: 2673-6357</identifier><identifier>EISSN: 2673-6357</identifier><identifier>DOI: 10.3390/hemato2040049</identifier><language>eng</language><publisher>Aviano: MDPI AG</publisher><subject>[11C]methionine ; [18F]FDG ; [18F]fluciclovine ; [68Ga]Ga-pentixafor ; Amino acids ; Anemia ; Biopsy ; Bone marrow ; Brain cancer ; Disease ; Medical prognosis ; Multiple myeloma ; Patients ; PET/CT ; Plasma ; Prostate cancer ; Radiation therapy ; Remission (Medicine) ; Tomography</subject><ispartof>Hemato, 2021-12, Vol.2 (4), p.727-738</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c333t-de5e1d818cd417401e865840de366fca2c0bf8dbba5e45348d8335bf91afa9323</citedby><cites>FETCH-LOGICAL-c333t-de5e1d818cd417401e865840de366fca2c0bf8dbba5e45348d8335bf91afa9323</cites><orcidid>0000-0003-4465-9635 ; 0000-0003-1096-0569 ; 0000-0003-3300-7420 ; 0000-0002-8762-0530</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2656384123/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2656384123?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590,75126</link.rule.ids></links><search><creatorcontrib>Revheim, Mona-Elisabeth</creatorcontrib><creatorcontrib>Stokke, Caroline</creatorcontrib><creatorcontrib>Nørgaard, Jakob Nordberg</creatorcontrib><creatorcontrib>Phillips, Hilde Feiring</creatorcontrib><creatorcontrib>Sherwani, Alexander Gul</creatorcontrib><creatorcontrib>Schjesvold, Fredrik</creatorcontrib><creatorcontrib>Connelly, James P.</creatorcontrib><title>New Targets for PET Imaging of Myeloma</title><title>Hemato</title><description>Recent advances in the treatment of multiple myeloma (MM) have increased the need for accurate diagnosis and detection of minimal residual disease (MRD), disease characterization and localization, and response evaluation and prognostication. Positron emission tomography (PET)/computed tomography (CT) imaging combines molecular and morphological information and has been shown to be especially valuable in this disease. The most frequently used PET tracer in MM is the glucose analog 18F-fluorodeoxyglucose ([18F]FDG). [18F]FDG PET/CT has a sensitivity for detection of MM between 80% to 100% and is currently the main imaging modality for assessing treatment response and for determining MRD. However, 18F-FDG PET/CT has some limitations, and imaging with alternative tracers that may overcome these constraints should be further explored. This article discusses new targets for PET/CT imaging in the assessment of MM.</description><subject>[11C]methionine</subject><subject>[18F]FDG</subject><subject>[18F]fluciclovine</subject><subject>[68Ga]Ga-pentixafor</subject><subject>Amino acids</subject><subject>Anemia</subject><subject>Biopsy</subject><subject>Bone marrow</subject><subject>Brain cancer</subject><subject>Disease</subject><subject>Medical prognosis</subject><subject>Multiple myeloma</subject><subject>Patients</subject><subject>PET/CT</subject><subject>Plasma</subject><subject>Prostate cancer</subject><subject>Radiation therapy</subject><subject>Remission (Medicine)</subject><subject>Tomography</subject><issn>2673-6357</issn><issn>2673-6357</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpVkM1Lw0AQxRdRsNQevQcEb9HZnU2yOUqptlA_DvW8bHZnY0rTrZsU6X9vtCJ6mS8evzc8xi453CCWcPtGremDAAkgyxM2EnmBaY5ZcfpnPmeTrlsDgFAcCslH7PqJPpKViTX1XeJDTF5mq2TRmrrZ1knwyeOBNqE1F-zMm01Hk58-Zq_3s9V0ni6fHxbTu2VqEbFPHWXEneLKOskLCZxUnikJjjDPvTXCQuWVqyqTkcxQKqcQs8qX3HhTosAxWxy5Lpi13sWmNfGgg2n09yHEWpvYN3ZDGslVjgaQL0mircxQAEpXCuAKh23Mro6sXQzve-p6vQ77uB3e1yLPclSSCxxU6VFlY-i6SP7XlYP-Slb_SxY_ATU4aiI</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Revheim, Mona-Elisabeth</creator><creator>Stokke, Caroline</creator><creator>Nørgaard, Jakob Nordberg</creator><creator>Phillips, Hilde Feiring</creator><creator>Sherwani, Alexander Gul</creator><creator>Schjesvold, Fredrik</creator><creator>Connelly, James P.</creator><general>MDPI AG</general><scope>AAYXX</scope><scope>CITATION</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4465-9635</orcidid><orcidid>https://orcid.org/0000-0003-1096-0569</orcidid><orcidid>https://orcid.org/0000-0003-3300-7420</orcidid><orcidid>https://orcid.org/0000-0002-8762-0530</orcidid></search><sort><creationdate>20211201</creationdate><title>New Targets for PET Imaging of Myeloma</title><author>Revheim, Mona-Elisabeth ; Stokke, Caroline ; Nørgaard, Jakob Nordberg ; Phillips, Hilde Feiring ; Sherwani, Alexander Gul ; Schjesvold, Fredrik ; Connelly, James P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c333t-de5e1d818cd417401e865840de366fca2c0bf8dbba5e45348d8335bf91afa9323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>[11C]methionine</topic><topic>[18F]FDG</topic><topic>[18F]fluciclovine</topic><topic>[68Ga]Ga-pentixafor</topic><topic>Amino acids</topic><topic>Anemia</topic><topic>Biopsy</topic><topic>Bone marrow</topic><topic>Brain cancer</topic><topic>Disease</topic><topic>Medical prognosis</topic><topic>Multiple myeloma</topic><topic>Patients</topic><topic>PET/CT</topic><topic>Plasma</topic><topic>Prostate cancer</topic><topic>Radiation therapy</topic><topic>Remission (Medicine)</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Revheim, Mona-Elisabeth</creatorcontrib><creatorcontrib>Stokke, Caroline</creatorcontrib><creatorcontrib>Nørgaard, Jakob Nordberg</creatorcontrib><creatorcontrib>Phillips, Hilde Feiring</creatorcontrib><creatorcontrib>Sherwani, Alexander Gul</creatorcontrib><creatorcontrib>Schjesvold, Fredrik</creatorcontrib><creatorcontrib>Connelly, James P.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Hemato</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Revheim, Mona-Elisabeth</au><au>Stokke, Caroline</au><au>Nørgaard, Jakob Nordberg</au><au>Phillips, Hilde Feiring</au><au>Sherwani, Alexander Gul</au><au>Schjesvold, Fredrik</au><au>Connelly, James P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New Targets for PET Imaging of Myeloma</atitle><jtitle>Hemato</jtitle><date>2021-12-01</date><risdate>2021</risdate><volume>2</volume><issue>4</issue><spage>727</spage><epage>738</epage><pages>727-738</pages><issn>2673-6357</issn><eissn>2673-6357</eissn><abstract>Recent advances in the treatment of multiple myeloma (MM) have increased the need for accurate diagnosis and detection of minimal residual disease (MRD), disease characterization and localization, and response evaluation and prognostication. Positron emission tomography (PET)/computed tomography (CT) imaging combines molecular and morphological information and has been shown to be especially valuable in this disease. The most frequently used PET tracer in MM is the glucose analog 18F-fluorodeoxyglucose ([18F]FDG). [18F]FDG PET/CT has a sensitivity for detection of MM between 80% to 100% and is currently the main imaging modality for assessing treatment response and for determining MRD. However, 18F-FDG PET/CT has some limitations, and imaging with alternative tracers that may overcome these constraints should be further explored. This article discusses new targets for PET/CT imaging in the assessment of MM.</abstract><cop>Aviano</cop><pub>MDPI AG</pub><doi>10.3390/hemato2040049</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-4465-9635</orcidid><orcidid>https://orcid.org/0000-0003-1096-0569</orcidid><orcidid>https://orcid.org/0000-0003-3300-7420</orcidid><orcidid>https://orcid.org/0000-0002-8762-0530</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2673-6357
ispartof Hemato, 2021-12, Vol.2 (4), p.727-738
issn 2673-6357
2673-6357
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_3edbdea5ef9e43cba43c009d920183a4
source Publicly Available Content Database
subjects [11C]methionine
[18F]FDG
[18F]fluciclovine
[68Ga]Ga-pentixafor
Amino acids
Anemia
Biopsy
Bone marrow
Brain cancer
Disease
Medical prognosis
Multiple myeloma
Patients
PET/CT
Plasma
Prostate cancer
Radiation therapy
Remission (Medicine)
Tomography
title New Targets for PET Imaging of Myeloma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T17%3A45%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20Targets%20for%20PET%20Imaging%20of%20Myeloma&rft.jtitle=Hemato&rft.au=Revheim,%20Mona-Elisabeth&rft.date=2021-12-01&rft.volume=2&rft.issue=4&rft.spage=727&rft.epage=738&rft.pages=727-738&rft.issn=2673-6357&rft.eissn=2673-6357&rft_id=info:doi/10.3390/hemato2040049&rft_dat=%3Cproquest_doaj_%3E2656384123%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c333t-de5e1d818cd417401e865840de366fca2c0bf8dbba5e45348d8335bf91afa9323%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2656384123&rft_id=info:pmid/&rfr_iscdi=true